menu

Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value

 

 
Please Note: Disclaimer for David Ross (U.S. Dept. Veterans Affairs): The views expressed are those of the author, and do not necessarily represent the policy or opinion of the US Department of Veterans Affairs, the Veterans Health Administration, or the US Government.
 

Meeting Summary

Slide Presentation

Speakers

  • Poonam Mishra, MD, Medical Officer, Division of Antiviral Products; FDA (10:46)
  • Gregg Alton, JD, Executive Vice President, Corporate and Medical Affairs; Gilead (17:07)
  • Steven Pearson, MD, MSc, President; Institute for Clinical and Economic Review (25:25)
  • Donna Cryer, JD, President and CEO; Global Liver Institute (34:10)
  • Michele Manos, PhD, MPH, DVM, Public Health Consultant (46:12)
  • David Ross, MD, PhD, MBI, Director, HIV, HCV, and Public Health Pathogens Programs, Office of Public Health/Clinical Public Health; VA (55:02)
  • Mark Godwin, PharmD, Manager of Clinical Pharmacy; UnitedHealthcare (1:07:01)
  • Followed by Discussion/Q&A (1:11:27)

Send questions, comments, and feedback to Els Houtsmuller.